Biotechnology
Filter News
Found 46,673 articles
-
Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting
3/15/2023
Homology Medicines, Inc. announced two presentations during the ACMG Annual Clinical Genetics Meeting, which highlight the preclinical data that supported initiation of the Company’s Phase 1 pheEDIT gene editing trial for phenylketonuria and the Phase 1 juMPStart gene therapy trial for Hunter syndrome.
-
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights
3/15/2023
Aura Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2022, and provided clinical development and operational highlights.
-
Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results
3/15/2023
Silence Therapeutics plc today reported its financial results for the fourth quarter and full year ended December 31, 2022 and reviewed recent business highlights.
-
Invitae to Present Data at The American Clinical Genetics Meeting 2023 That Supports Removing Barriers to Genetic Testing
3/15/2023
Invitae, a leading medical genetics company, announced seven studies, including one oral presentation and six posters, to be presented at the 2023 American Clinical Genetics Meeting held in Salt Lake City from March 14-18, 2023.
-
Miltenyi Biotec acquires biosensor company lino Biotech
3/15/2023
lino Biotech announced it has been acquired by Miltenyi Biotec, a global biotech company based in Germany, on February 22, 2023.
-
MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results
3/15/2023
MaxCyte, Inc. announced its fourth quarter and full year ended December 31, 2022, financial results and provided initial 2023 revenue guidance.
-
Century Therapeutics to Present at the AACR Annual Meeting 2023
3/15/2023
Century Therapeutics announced that preclinical data from the Company’s iPSC-based cell therapy platform will be presented in a poster at the American Association for Cancer Research Annual Meeting on Monday, April 17, 2023.
-
Tempo Bioscience Expands Human Liver Models for Toxicity Evaluation and Disease Modeling
3/15/2023
Tempo Bioscience, Inc., a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell derived cell products and affiliated cell-based services.
-
Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies
3/15/2023
Mediar Therapeutics Inc. announced a $105M financing, including a recent $85 million Series A round co-led by Novartis Venture Fund and Sofinnova Partners and with participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol Myers Squibb, Eli Lilly & Company, Ono Venture Investment and Mass General Brigham Ventures.
-
Rare Earth Elements Collected from Wastewater Utilizing Cyanobacteria Now Patent Pending
3/15/2023
Yasheng Group, an agricultural and biotech company with U.S. headquarters in San Jose, California announced that HERB gained patent protection under the USPTO, entitled, “Method for Using Cyanobacteria to Collect Rare Earth Elements from Wastewater.”.
-
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting
3/15/2023
Tango Therapeutics, Inc. announced the acceptance of two oral and two poster presentations at the American Association for Cancer Research 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida.
-
Telo Genomics Advances to Final Stage of Achieving ISO Certification
3/15/2023
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce that it has recently completed the interim assessment of its systems and protocols for ISO 15189 certification with over 90% compliance.
-
Gritstone bio Announces Presentations on Neoantigen Prediction Capabilities and Cancer Vaccine Programs at the 2023 AACR Annual Meeting
3/15/2023
Gritstone bio, Inc. today announced multiple presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023 in Orlando, Florida.
-
Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
3/15/2023
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2022.
-
Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023
3/15/2023
Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that the American Association for Cancer Research (AACR) has accepted an abstract on its Decoy anti-tumor platform for its annual scientific conference on April 14-19, 2023 in Orlando.
-
Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023
3/15/2023
Dyadic International, Inc. today announced that it will report its financial results for the year ended 2022 and host a corporate update conference call on Wednesday, March 29, 2023.
-
Cambrian BioPharma announced the launch of Amplifier Therapeutics, a biotech focused on developing a clinical-stage AMPK activator.
-
To hone in on its growth areas, Novartis is looking to trim its ophthalmology portfolio and sell off some of its assets, according to a Bloomberg report published Tuesday.
-
Novan Announces $6.0 Million Registered Direct Offering
3/14/2023
Novan, Inc., announced that it has entered into definitive agreements for the issuance and sale in a registered direct offering of an aggregate of 5,042,017 shares of its common stock and warrants to purchase up to 5,042,017 shares of common stock, at an effective combined purchase price of $1.19 per share and associated Common Warrant.
-
PacBio Announces a New Informatics Analysis Method for Highly Homologous Genes
3/14/2023
PacBio, a leading developer of highly accurate sequencing solutions, announced a new informatics method that genotypes gene paralogs and pseudogenes with high accuracy.